Pharmaceutical Benefits Scheme - listing of Strattera® (atomoxetine)

he new drug, Strattera® (atomoxetine), will be available through the PBS for some young people aged 6 to 18 with attention deficit hyperactivity disorder (ADHD).

Page last updated: 08 May 2007

PDF printable version of Pharmaceutical Benefits Scheme - listing of Strattera® (atomoxetine) (PDF 628 KB)

Why is this important?

  • A new drug, Strattera® (atomoxetine), has been recommended for listing for the treatment of attention deficit hyperactivity disorder (ADHD) for those between the ages of six and 18 years who are unable to take stimulants.
  • ADHD is a neuro-behavioural syndrome in which symptoms of hyperactivity and/or inattention cause impairment in social, academic or occupational functioning.
  • Strattera® will become available on the Pharmaceutical Benefits Scheme (PBS) from 1 July 2007 for the treatment of ADHD with initial treatment to be prescribed by a paediatrician or psychiatrist only.

Who will benefit?

  • It is expected that about 18,000 people will commence Strattera® in the first full financial year of listing. People who need to buy Strattera® for authorised use will now only pay the general fee of $30.70 per script or the concessional rate of $4.90 per script.

What funding is the Government committing to this initiative?

  • The annual cost to Government of listing Strattera® on the PBS will be about $962 for the average patient per year. The listing of Strattera® will add around $101.6 million over four years to the PBS. This includes funding for administering payments through Medicare Australia.

What have we done in the past?

  • The Government funds other drugs for the treatment of attention deficit hyperactivity disorder (ADHD). However, these are not suitable for all children.

When will the initiative conclude?

  • This is an ongoing initiative.

In this section